Assessing the efficacy‐effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population‐based, real‐world data for contemporary parenteral cancer therapeutics
出版年份 2020 全文链接
标题
Assessing the efficacy‐effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population‐based, real‐world data for contemporary parenteral cancer therapeutics
作者
关键词
-
出版物
CANCER
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-01-08
DOI
10.1002/cncr.32697
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Real-world data: towards achieving the achievable in cancer care
- (2019) Christopher M. Booth et al. Nature Reviews Clinical Oncology
- Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness
- (2018) Jacqueline Corrigan-Curay et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Systematic evaluation of the efficacy–effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer
- (2018) Christine M. Cramer-van der Welle et al. EUROPEAN RESPIRATORY JOURNAL
- HEALTH TECHNOLOGY PERFORMANCE ASSESSMENT: REAL-WORLD EVIDENCE FOR PUBLIC HEALTHCARE SUSTAINABILITY
- (2017) Augusto Afonso Guerra-Júnior et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
- (2017) Véronique Diéras et al. LANCET ONCOLOGY
- Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
- (2017) Ian E Krop et al. LANCET ONCOLOGY
- Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework
- (2017) Darius N. Lakdawalla et al. VALUE IN HEALTH
- Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies
- (2016) A. Srikanthan et al. CANCER TREATMENT REVIEWS
- Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
- (2016) Jorge A. Marrero et al. JOURNAL OF HEPATOLOGY
- Economic downturns, universal health coverage, and cancer mortality in high-income and middle-income countries, 1990–2010: a longitudinal analysis
- (2016) Mahiben Maruthappu et al. LANCET
- Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial
- (2016) Mathias Rummel et al. LANCET ONCOLOGY
- Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
- (2016) H. K. Sanoff et al. ONCOLOGIST
- A Systematic Literature Review On The Drivers of Effectiveness and The Efficacy-Effectiveness Gap in Hematological Malignancies with A Focus On Hodgkin’s Lymphoma
- (2016) L Liu et al. VALUE IN HEALTH
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study
- (2015) V Goede et al. LEUKEMIA
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence
- (2014) C M Booth et al. BRITISH JOURNAL OF CANCER
- Mind the gap: Efficacy versus effectiveness and pivotal prostate cancer clinical trial demographics
- (2014) Matthew D. Galsky et al. CANCER
- Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses
- (2014) Bertrand Coiffier et al. Journal of Hematology & Oncology
- Improved Survival with Bevacizumab in Advanced Cervical Cancer
- (2014) Krishnansu S. Tewari et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Primer on Effectiveness and Efficacy Trials
- (2014) Amit G Singal et al. Clinical and Translational Gastroenterology
- Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials*
- (2013) A. J. Templeton et al. ANNALS OF ONCOLOGY
- Patient Income Level and Cancer Clinical Trial Participation
- (2013) Joseph M. Unger et al. JOURNAL OF CLINICAL ONCOLOGY
- PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2013) Luis G. Paz-Ares et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
- (2012) Patricia Guyot et al. BMC Medical Research Methodology
- Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial
- (2012) Wolfgang U. Knauf et al. BRITISH JOURNAL OF HAEMATOLOGY
- Effectiveness of Bevacizumab With First-Line Combination Chemotherapy for Medicare Patients With Stage IV Colorectal Cancer
- (2012) Jeffrey A. Meyerhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma
- (2012) Jesús F. San Miguel et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy vs. effectiveness: Erlotinib in previously treated non-small-cell lung cancer
- (2012) Naureen Sheikh et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Comparative Effectiveness of Different Chemotherapeutic Regimens on Survival of People Aged 66 and Older with Stage III Colon Cancer: A “Real World” Analysis Using Surveillance, Epidemiology, and End Results-Medicare Data
- (2011) Fei-Yuan Hsiao et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
- (2011) Javier Cortes et al. LANCET
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
- (2010) Jean-Luc Harousseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Generalizing the Results of Cancer Clinical Trials
- (2009) Ralph M. Meyer JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
- (2009) Pierre Fenaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Making trials matter: pragmatic and explanatory trials and the problem of applicability
- (2009) Shaun Treweek et al. Trials
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now